{
  "annotationGroups" : [ {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244022",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244022",
    "name" : "*1/*2",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*2)/Normal function (CYP2C9*1)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445374,
      "html" : "<p>Genetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445375,
      "html" : "<p>Intermediate Metabolizer</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451445376,
      "html" : "<p><em>CYP2C9*1/*2</em> genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445377,
      "html" : "<p>NO action is required for this gene-drug interaction.</p>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244024",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244024",
    "name" : "*2/*2",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*2)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445422,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445423,
      "html" : "<p>Poor Metabolizer</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451445424,
      "html" : "<p><em>CYP2C9*2/*2</em> genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445425,
      "html" : "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244023",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244023",
    "name" : "*1/*3",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*3)/Normal function (CYP2C9*1)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445378,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445379,
      "html" : "<p>Intermediate Metabolizer</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451445420,
      "html" : "<p><em>CYP2C9*1/*3</em> genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445421,
      "html" : "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244025",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244025",
    "name" : "*2/*3",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*3)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445426,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445427,
      "html" : "<p>Poor Metabolizer</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451445428,
      "html" : "<p><em>CYP2C9*2/*3</em> genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445429,
      "html" : "<ol>\n<li>use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244026",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244026",
    "name" : "*3/*3",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*3)/Decreased function (CYP2C9*3)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445430,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445431,
      "html" : "<p>Poor Metabolizer</p>\n",
      "version" : 0
    },
    "phenotype" : {
      "id" : 1451445432,
      "html" : "<p><em>CYP2C9*3/*3</em> genotype</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445433,
      "html" : "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244041",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244041",
    "name" : "Poor Metabolizer",
    "genePhenotypes" : [ "CYP2C9:Decreased function (CYP2C9*2)/No function", "CYP2C9:Decreased function (CYP2C9*3)/No function", "CYP2C9:Decreased function/Decreased function", "CYP2C9:Decreased function/Decreased function (CYP2C9*2)", "CYP2C9:Decreased function/Decreased function (CYP2C9*3)", "CYP2C9:Decreased function/No function", "CYP2C9:No function/No function" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445380,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445381,
      "html" : "<p>Poor Metabolizer</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445382,
      "html" : "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244027",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244027",
    "name" : "Normal Metabolizer",
    "genePhenotypes" : [ "CYP2C9:Normal function (CYP2C9*1)/Normal function (CYP2C9*1)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445437,
      "html" : "<p>The guideline does not provide a description of the impact of a normal metabolizer phenotype on warfarin.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445438,
      "html" : "<p>Normal Metabolizer</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445439,
      "html" : "<p>The guideline does not provide a recommendation for warfarin in normal metabolizers.</p>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  }, {
    "@id" : "https://pharmgkb.org/dosingGuidelineAnnotationGroup/PA166244021",
    "@context" : "https://api.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "objCls" : "Dosing Guideline Annotation Group",
    "id" : "PA166244021",
    "name" : "Intermediate Metabolizer",
    "genePhenotypes" : [ "CYP2C9:Decreased function/Normal function (CYP2C9*1)", "CYP2C9:No function/Normal function (CYP2C9*1)" ],
    "guideline" : {
      "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
      "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
      "objCls" : "Guideline Annotation",
      "id" : "PA166182842",
      "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
      "version" : 4
    },
    "implications" : {
      "id" : 1451445371,
      "html" : "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n",
      "version" : 0
    },
    "metabolizerStatus" : {
      "id" : 1451445372,
      "html" : "<p>Intermediate Metabolizer</p>\n",
      "version" : 0
    },
    "recommendation" : {
      "id" : 1451445373,
      "html" : "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n",
      "version" : 0
    },
    "rxChangeStatus" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/rxChange/rxChange:1448602497",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602497,
      "parents" : [ ],
      "resource" : "Prescribing Change",
      "term" : "Yes",
      "termId" : "rxChange:1448602497",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://pharmgkb.org/ontologyTerm/guidelineStrength/guidelineStrength:981501929",
      "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501929,
      "description" : "Not Applicable",
      "parents" : [ ],
      "resource" : "Guideline Strength",
      "term" : "N/A",
      "termId" : "guidelineStrength:981501929",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 0
  } ],
  "citations" : [ ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182842",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166182842",
    "name" : "Annotation of DPWG Guideline for warfarin and CYP2C9",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "guidelineGenes" : [ {
      "id" : 1451445360,
      "alleles" : [ {
        "id" : 1451445367,
        "_label" : "*1",
        "allele" : "*1",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1451444660",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1451444660,
          "description" : "for extended dosing guidelines on DPWG CYP2C9 guidelines",
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Normal function (CYP2C9*1)",
          "termId" : "alleleFunction:1451444660",
          "version" : 0
        },
        "version" : 0
      }, {
        "id" : 1451445368,
        "_label" : "*2",
        "allele" : "*2",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1451444630",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1451444630,
          "description" : "for extended dosing guidelines on DPWG CYP2C9 guidelines",
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function (CYP2C9*2)",
          "termId" : "alleleFunction:1451444630",
          "version" : 0
        },
        "version" : 0
      }, {
        "id" : 1451445369,
        "_label" : "*3",
        "allele" : "*3",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1451444680",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1451444680,
          "description" : "for extended dosing guidelines on DPWG CYP2C9 guidelines",
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function (CYP2C9*3)",
          "termId" : "alleleFunction:1451444680",
          "version" : 1
        },
        "version" : 0
      }, {
        "id" : 1451445361,
        "_label" : "*4",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816545",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816545",
          "symbol" : "CYP2C9*4",
          "name" : "*4",
          "version" : 21
        },
        "version" : 0
      }, {
        "id" : 1451445362,
        "_label" : "*5",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816546",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816546",
          "symbol" : "CYP2C9*5",
          "name" : "*5",
          "version" : 21
        },
        "version" : 0
      }, {
        "id" : 1451445363,
        "_label" : "*6",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558515,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "No function",
          "termId" : "haplotypeTags:1445558515",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816547",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816547",
          "symbol" : "CYP2C9*6",
          "name" : "*6",
          "version" : 22
        },
        "version" : 0
      }, {
        "id" : 1451445364,
        "_label" : "*8",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816549",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816549",
          "symbol" : "CYP2C9*8",
          "name" : "*8",
          "version" : 23
        },
        "version" : 0
      }, {
        "id" : 1451445365,
        "_label" : "*11",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816552",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816552",
          "symbol" : "CYP2C9*11",
          "name" : "*11",
          "version" : 21
        },
        "version" : 0
      }, {
        "id" : 1451445366,
        "_label" : "*12",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "haplotype" : {
          "@id" : "https://pharmgkb.org/haplotype/PA165816553",
          "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
          "objCls" : "Haplotype",
          "id" : "PA165816553",
          "symbol" : "CYP2C9*12",
          "name" : "*12",
          "version" : 21
        },
        "version" : 0
      }, {
        "id" : 1451445370,
        "_label" : "*13",
        "allele" : "*13",
        "function" : {
          "@id" : "https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331",
          "@context" : "https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld",
          "id" : 1445558331,
          "parents" : [ ],
          "resource" : "Allele Function",
          "term" : "Decreased function",
          "termId" : "haplotypeTags:1445558331",
          "version" : 1
        },
        "version" : 0
      } ],
      "gene" : {
        "@id" : "https://pharmgkb.org/gene/PA126",
        "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
        "objCls" : "Gene",
        "id" : "PA126",
        "symbol" : "CYP2C9",
        "name" : "cytochrome P450 family 2 subfamily C member 9",
        "alleleFile" : "CYP2C9_allele_definition_table.xlsx",
        "altNames" : {
          "synonym" : [ "cytochrome P450, family 2, subfamily C, polypeptide 9" ],
          "symbol" : [ "CYP2C10", "P450IIC9" ]
        },
        "buildVersion" : "GRCh38.p7",
        "cbStart" : "q23.33",
        "cbStop" : "q23.33",
        "chr" : {
          "@id" : "https://pharmgkb.org/chromosome/PA504",
          "@context" : "https://api.pharmgkb.org/jsonld/chromosome.jsonld",
          "objCls" : "Chromosome",
          "id" : "PA504",
          "name" : "chr10",
          "version" : 3
        },
        "chrStartPosB37" : 96698350,
        "chrStartPosB38" : 94905867,
        "chrStopPosB37" : 96749486,
        "chrStopPosB38" : 94989395,
        "cpicGene" : true,
        "crossReferences" : [ {
          "@id" : "https://pharmgkb.org/crossReference/alfred/LO000304H",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 124544684,
          "resource" : "ALFRED",
          "resourceId" : "LO000304H",
          "_url" : "http://alfred.med.yale.edu/alfred/recordinfop.asp?UNID=LO000304H",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ctd/1559",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 553242511,
          "resource" : "Comparative Toxicogenomics Database",
          "resourceId" : "1559",
          "_url" : "http://ctdbase.org/detail.go?type=gene&acc=1559",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ensembl/ENSG00000138109",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 132256030,
          "resource" : "Ensembl",
          "resourceId" : "ENSG00000138109",
          "_url" : "http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138109",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/genAtlas/CYP2C9",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 73374,
          "resource" : "GenAtlas",
          "resourceId" : "CYP2C9",
          "_url" : "http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=CYP2C9",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/geneCard/CYP2C9",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 88302,
          "resource" : "GeneCard",
          "resourceId" : "CYP2C9",
          "_url" : "http://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP2C9",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005506",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34969,
          "resource" : "GO",
          "resourceId" : "GO:0005506",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005506",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005783",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34654,
          "resource" : "GO",
          "resourceId" : "GO:0005783",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005783",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0005792",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 35016,
          "resource" : "GO",
          "resourceId" : "GO:0005792",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0005792",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0006118",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 35063,
          "resource" : "GO",
          "resourceId" : "GO:0006118",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0006118",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0016020",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 34795,
          "resource" : "GO",
          "resourceId" : "GO:0016020",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0016020",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0016712",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 8676615,
          "resource" : "GO",
          "resourceId" : "GO:0016712",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0016712",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0018675",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 130200545,
          "resource" : "GO",
          "resourceId" : "GO:0018675",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0018675",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0018676",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 62330469,
          "resource" : "GO",
          "resourceId" : "GO:0018676",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0018676",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0020037",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 77774616,
          "resource" : "GO",
          "resourceId" : "GO:0020037",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0020037",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/go/GO:0046872",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 746292,
          "resource" : "GO",
          "resourceId" : "GO:0046872",
          "_url" : "http://amigo.geneontology.org/amigo/term/GO%3A0046872",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/hgnc/HGNC:2623",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608087481,
          "resource" : "HGNC",
          "resourceId" : "HGNC:2623",
          "_url" : "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC%3A2623",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/HumanCycGene/HS06458",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608087488,
          "resource" : "HumanCyc Gene",
          "resourceId" : "HS06458",
          "_url" : "http://biocyc.org/HUMAN/NEW-IMAGE?object=HS06458",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/modBase/P11712",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 560877670,
          "resource" : "ModBase",
          "resourceId" : "P11712",
          "_url" : "http://salilab.org/modbase/search?modelflag=longest&databaseID=P11712",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/mutDb/CYP2C9",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 455912,
          "resource" : "MutDB",
          "resourceId" : "CYP2C9",
          "_url" : "http://www.mutdb.org/genes/search?_method=POST&data%5BSearch%5D%5Bidentifier%5D=CYP2C9",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/entrezGene/1559",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 10746,
          "resource" : "NCBI Gene",
          "resourceId" : "1559",
          "_url" : "https://www.ncbi.nlm.nih.gov/gene/1559",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/omim/122700",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 560556297,
          "resource" : "OMIM",
          "resourceId" : "122700",
          "_url" : "http://omim.org/entry/122700",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/omim/601130",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 4208,
          "resource" : "OMIM",
          "resourceId" : "601130",
          "_url" : "http://omim.org/entry/601130",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/pharmVarGene/CYP2C9",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 1451280330,
          "resource" : "PharmVar Gene",
          "resourceId" : "CYP2C9",
          "_url" : "https://www.pharmvar.org/gene/CYP2C9",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqDna/NG_008385",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 560556313,
          "resource" : "RefSeq DNA",
          "resourceId" : "NG_008385",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NG_008385",
          "version" : 0
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqDna/NT_030059",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 37037,
          "resource" : "RefSeq DNA",
          "resourceId" : "NT_030059",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NT_030059",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqProtein/NP_000762",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 37898,
          "resource" : "RefSeq Protein",
          "resourceId" : "NP_000762",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NP_000762",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/refSeqRna/NM_000771",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 46973,
          "resource" : "RefSeq RNA",
          "resourceId" : "NM_000771",
          "_url" : "https://www.ncbi.nlm.nih.gov/nuccore/NM_000771",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/ucscGenomeBrowser/NM_000771",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 122290,
          "resource" : "UCSC Genome Browser",
          "resourceId" : "NM_000771",
          "_url" : "http://genome.ucsc.edu/cgi-bin/hgTracks?Submit=Submit&position=NM_000771",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/uniProtKb/P11712",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 62330450,
          "name" : "CP2C9_HUMAN",
          "resource" : "UniProtKB",
          "resourceId" : "P11712",
          "_url" : "http://www.uniprot.org/uniprot/P11712",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/uniProtKb/Q5VX92",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 608087487,
          "name" : "Q5VX92_HUMAN",
          "resource" : "UniProtKB",
          "resourceId" : "Q5VX92",
          "_url" : "http://www.uniprot.org/uniprot/Q5VX92",
          "version" : 1
        }, {
          "@id" : "https://pharmgkb.org/crossReference/url/http://www.imm.ki.se/CYPalleles/cyp2c9.htm",
          "@context" : "https://api.pharmgkb.org/jsonld/crossReference.jsonld",
          "id" : 87,
          "resource" : "URL",
          "resourceId" : "http://www.imm.ki.se/CYPalleles/cyp2c9.htm",
          "_url" : "http://www.imm.ki.se/CYPalleles/cyp2c9.htm",
          "version" : 1
        } ],
        "hasNonStandardHaplotypes" : false,
        "hideHaplotypes" : false,
        "pharmVarGene" : true,
        "strand" : "plus",
        "terms" : [ {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0004497","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560498878,"_url":"http://amigo.geneontology.org/amigo/term/GO:0004497","resource":"Gene Ontology","term":"monooxygenase activity","termId":"GO:0004497"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005783","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500134,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005783","resource":"Gene Ontology","term":"endoplasmic reticulum","termId":"GO:0005783"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005789","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500141,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005789","resource":"Gene Ontology","term":"endoplasmic reticulum membrane","termId":"GO:0005789"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0005792","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500144,"_url":"http://amigo.geneontology.org/amigo/term/GO:0005792","resource":"Gene Ontology","term":"microsome","termId":"GO:0005792"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0008144","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560499864,"_url":"http://amigo.geneontology.org/amigo/term/GO:0008144","resource":"Gene Ontology","term":"drug binding","termId":"GO:0008144"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0008202","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560501294,"_url":"http://amigo.geneontology.org/amigo/term/GO:0008202","resource":"Gene Ontology","term":"steroid metabolic process","termId":"GO:0008202"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0008395","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560496176,"_url":"http://amigo.geneontology.org/amigo/term/GO:0008395","resource":"Gene Ontology","term":"steroid hydroxylase activity","termId":"GO:0008395"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0009055","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560503412,"_url":"http://amigo.geneontology.org/amigo/term/GO:0009055","resource":"Gene Ontology","term":"electron carrier activity","termId":"GO:0009055"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0016020","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560499972,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016020","resource":"Gene Ontology","term":"membrane","termId":"GO:0016020"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0016098","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560506711,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016098","resource":"Gene Ontology","term":"monoterpenoid metabolic process","termId":"GO:0016098"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0016491","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560495264,"_url":"http://amigo.geneontology.org/amigo/term/GO:0016491","resource":"Gene Ontology","term":"oxidoreductase activity","termId":"GO:0016491"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0017144","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560507281,"_url":"http://amigo.geneontology.org/amigo/term/GO:0017144","resource":"Gene Ontology","term":"drug metabolic process","termId":"GO:0017144"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0018675","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560508105,"_url":"http://amigo.geneontology.org/amigo/term/GO:0018675","resource":"Gene Ontology","term":"(S)-limonene 6-monooxygenase activity","termId":"GO:0018675"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0018676","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560508106,"_url":"http://amigo.geneontology.org/amigo/term/GO:0018676","resource":"Gene Ontology","term":"(S)-limonene 7-monooxygenase activity","termId":"GO:0018676"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0019627","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560495074,"_url":"http://amigo.geneontology.org/amigo/term/GO:0019627","resource":"Gene Ontology","term":"urea metabolic process","termId":"GO:0019627"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0019825","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560509226,"_url":"http://amigo.geneontology.org/amigo/term/GO:0019825","resource":"Gene Ontology","term":"oxygen binding","termId":"GO:0019825"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0020037","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560509358,"_url":"http://amigo.geneontology.org/amigo/term/GO:0020037","resource":"Gene Ontology","term":"heme binding","termId":"GO:0020037"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0032787","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560500462,"_url":"http://amigo.geneontology.org/amigo/term/GO:0032787","resource":"Gene Ontology","term":"monocarboxylic acid metabolic process","termId":"GO:0032787"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0033767","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560513624,"_url":"http://amigo.geneontology.org/amigo/term/GO:0033767","resource":"Gene Ontology","term":"4-hydroxyacetophenone monooxygenase activity","termId":"GO:0033767"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0034875","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560514701,"_url":"http://amigo.geneontology.org/amigo/term/GO:0034875","resource":"Gene Ontology","term":"caffeine oxidase activity","termId":"GO:0034875"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0042737","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560515689,"_url":"http://amigo.geneontology.org/amigo/term/GO:0042737","resource":"Gene Ontology","term":"drug catabolic process","termId":"GO:0042737"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0042738","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560515690,"_url":"http://amigo.geneontology.org/amigo/term/GO:0042738","resource":"Gene Ontology","term":"exogenous drug catabolic process","termId":"GO:0042738"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0043603","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560509048,"_url":"http://amigo.geneontology.org/amigo/term/GO:0043603","resource":"Gene Ontology","term":"cellular amide metabolic process","termId":"GO:0043603"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0046872","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560495445,"_url":"http://amigo.geneontology.org/amigo/term/GO:0046872","resource":"Gene Ontology","term":"metal ion binding","termId":"GO:0046872"}, {"@id":"https://pharmgkb.org/ontologyTerm/GO/GO:0055114","@context":"https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":560509993,"_url":"http://amigo.geneontology.org/amigo/term/GO:0055114","resource":"Gene Ontology","term":"oxidation reduction","termId":"GO:0055114"} ],
        "version" : 7876
      },
      "version" : 0
    } ],
    "hasTestingGuidance" : false,
    "history" : [ {
      "id" : 1450415240,
      "date" : "2019-05-27T00:00:00-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450820676,
      "date" : "2019-10-03T16:23:52.557-07:00",
      "description" : "No changes based on August 2019 guidelines",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450963944,
      "date" : "2020-02-11T08:29:07-08:00",
      "description" : "Fixed links to 2018 guideline pdfs.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450963980,
      "date" : "2020-02-11T08:45:28.833-08:00",
      "description" : "Fixed links to the algorithms.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451445822,
      "date" : "2021-05-18T00:00:00-07:00",
      "description" : "Added extended dosing",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451699920,
      "date" : "2022-03-01T13:20:35.572-08:00",
      "description" : "Updated names of IM and PM groups and added footnote and explanation.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451704181,
      "date" : "2022-03-03T16:33:22.822-08:00",
      "description" : "Annotation current with May 2021 DPWG Guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451732821,
      "date" : "2022-03-28T09:57:36.474-07:00",
      "description" : "Annotation current with February 2022 DPWG guideline release",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}],"objCls":"Literature"}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}],"objCls":"Literature"} ],
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/haplotype/PA165816543",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165816543",
      "symbol" : "CYP2C9*2",
      "name" : "*2",
      "version" : 21
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165816544",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165816544",
      "symbol" : "CYP2C9*3",
      "name" : "*3",
      "version" : 23
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA451906",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451906",
      "name" : "warfarin",
      "version" : 16
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA126",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA126",
      "symbol" : "CYP2C9",
      "name" : "cytochrome P450 family 2 subfamily C member 9",
      "version" : 7876
    } ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1450415238,
      "html" : "<p>Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. &quot;The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>&quot;</p>\n",
      "version" : 1
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1450415239,
      "html" : "<h3 id=\"may-2021-update\">May 2021 update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has made some minor changes to the names of some phenotype groups in this guideline. The table below has been updated to reflect this but the recommendations themselves have not changed.</p>\n<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for warfarin based on CYP2C9 genotype/phenotype.  They recommend reducing warfarin dose for CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype.The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2C9 IM other<sup>a</sup></td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</td>\n</tr>\n<tr>\n<td>CYP2C9 PM other<sup>a</sup></td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</td>\n</tr>\n<tr>\n<td>CYP2C9*1/*2</td>\n<td>warfarin</td>\n<td>Genetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual.</td>\n<td>NO action is required for this gene-drug interaction.</td>\n</tr>\n<tr>\n<td>CYP2C9*1/*3</td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td>\n</tr>\n<tr>\n<td>CYP2C9*2/*2</td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td>\n</tr>\n<tr>\n<td>CYP2C9*2/*3</td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td>\n</tr>\n<tr>\n<td>CYP2C9*3/*3</td>\n<td>warfarin</td>\n<td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td>\n<td>1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td>\n</tr>\n</tbody>\n</table>\n<p><sup>a</sup> These groups are referred to in the DPWG recommendation PDF as 'IM ANDERS' and 'PM ANDERS', which use the Dutch word 'anders'. PharmGKB has translated these as 'IM other' and PM other', respectively.</p>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0006232.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n",
      "version" : 3
    },
    "userId" : "lgong",
    "version" : 4
  }
}